Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMT + Durvalumab + Chemotherapy in Advanced/Metastatic Adenocarcinoma NSCLC
NCT04105270Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2022
- Primary completion
- Jan 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Restorative Microbiota Therapy in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Masonic Cancer Center. Primary endpoints: Progression Free Survival at 3 Years and Safety and tolerability of RMT at 2 Years. Started Nov 2022; status: recruiting.
02
Drugs
Restorative Microbiota Therapy
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04105270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105270.